Structure Therapeutics Inc. American Depositary Shares closed at $19.84 on Nov 12, down 5.30%, 78.8% below its 52-week closing high. Volume of 1.0M shares was 1.03× its 20-day average (close to normal).
Split-adjusted performance: -9.3% over one month, -50.2% over six months, -43.1% over one year.
Short interest was 5.9M shares at the Oct 30 settlement, down 17.1% from the prior report (6.5 days to cover).
No reported quarters with price history yet.
Percentile among 417 companies (100 = best)
Industry medians: 6-month return −26.3%, revenue growth +9.3%, net margin −35.1%, P/E 16.5×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| GPCRStructure Therapeutics | $19.84 | −5.30% | −50.2% | — | — | — | $1.41B | |
| CMPSCOMPASS Pathways Plc American Depository Shares | $9.12 | −1.94% | −14.1% | — | — | — | $1.29B | Compare |
| SLNSilence Therapeutics Plc American Depository Share | $19.80 | +0.15% | +177.7% | — | — | — | $1.23B | Compare |
| ZLABZai Lab Limited | $26.04 | −1.44% | +28.1% | −6.8% | −42.6% | — | $3.22B | Compare |
| AMRNAmarin | $11.67 | −0.34% | −21.0% | −20.4% | 0.6% | — | $490.6M | Compare |
| BCYCBicycle Therapeutics | $3.45 | −6.50% | −26.1% | +190.2% | −30.8% | — | $241.8M | Compare |
| KZIAKazia Therapeutics Limited | $6.95 | −6.46% | −49.7% | — | — | — | $108.1M | Compare |
| MREOMereo BioPharma Group | $0.3050 | −0.52% | +24.0% | — | — | — | $48.7M | Compare |
| ONCBeOne Medicines | $415.96 | −0.96% | +36.6% | +33.8% | 20.4% | 51.9 | $47.51B | Compare |
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
